AUGUST 26, 2024

FDA Approves LONSURF With Bevacizumab for Previously Treated mCRC

The FDA approved trifluridine and tipiracil (LONSURF, Taiho Oncology) with bevacizumab, for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor biological therapy, and if RAS wild-type, an anti-epidermal growth factor receptor therapy. The FDA had previously approved single-agent LONSURF for this indication in September 2015.

Safety and efficacy were evaluated in SUNLIGHT, an